Previous 10 | Next 10 |
home / stock / lexxw / lexxw news
(TheNewswire) Third Party Analysis for Biotech and Pharma Industries Kelowna, British Columbia – TheNewswire - August 11, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a glob...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced its receipt of a positive full written response from the Food and Drug Administration (“FDA”) from its pre-Investigational New Drug (“Pre-IND”) meeting regar...
(TheNewswire) Significant Milestone Achieved in Commercial Product Development Program Abbreviated 505(b)(2) Strategy Confirmed as an Appropriate NDA Pathway Kelowna, British Columbia – TheNewswire - August 10, 2022 – Lexaria B...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that dosing with its DehydraTECH(TM)-processed cannabidiol (“DehydraTECH-CBD”) has been completed in its multi-week human clinical hypertension study HYPER-H21-4. Accordin...
(TheNewswire) Kelowna, British Columbia – TheNewswire - July 27, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce th...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that its exclusive* Japanese licensee, Premier Wellness Science Co. Ltd., officially launched the first generation of its new cannabidiol (“CBD”) products under the brand ...
(TheNewswire) Kelowna, British Columbia – TheNewswire - July 26, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce th...
(TheNewswire) Kelowna, British Columbia – TheNewswire - July 14, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is please...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the pending start of its upcoming human nicotine study NIC-H22-1. Through the study, Lexaria expects to evidence that processing purified nicotine with its patented drug delivery techno...
(TheNewswire) Lexaria is targeting the oral nicotine pouch category, one of the fastest growing segments of the nicotine industry. Kelowna, British Columbia – TheNewswire - July 13, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Na...
News, Short Squeeze, Breakout and More Instantly...
Lexaria Bioscience Corp. Warrant Company Name:
LEXXW Stock Symbol:
NASDAQ Market:
Lexaria Bioscience Corp. Warrant Website:
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1. The company noted that the results have already produced several notewort...
(TheNewswire) DehydraTECH appears to work with a second GLP-1 drug – liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 D...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, is preparing for growth by executing a strategic growth plan. A key element of the plan includes expanding the company’s management team to enable efficient handling of a greater workload of projects ...